Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: Outcome of a large array of in vivo and ex vivo tests

Journal of Applied Physiology

Volumn 106, Issue 4, 2009, Pages 1311-1324

  Burdi, Rosa ^a   Rolland, Jean François ^a   Fraysse, Bodvael ^a,e   Litvinova, Karina ^a   Cozzoli, Anna ^a   Giannuzzi, Viviana ^a   Liantonio, Antonella ^a   Camerino, Giulia Maria ^a   Sblendorio, Valeriana ^a,b   Capogrosso, Roberta Francesca ^a   Palmieri, Beniamino ^b   Andreetta, Francesca ^c   Confalonieri, Paolo ^c   De Benedictis, Leonarda ^a   Montagnani, Monica ^a   De Luca, Annamaria ^a,d  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d Dipartimento Farmacobiologico   (Italy)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Calcium homeostasis; Exercise; Muscular dystrophy; Oxidative stress; Phosphodiesterase inhibitors; Preclinical test

Indexed keywords

CREATINE KINASE; HYDROETHIDINE; NERVE CELL ADHESION MOLECULE; PENTOXIFYLLINE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; CALCIUM; FLUORESCENT DYE; FURA 2; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; EXTENSOR DIGITORUM LONGUS MUSCLE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; MOUSE; MUSCLE TETANIC CONTRACTION; MUSCULAR DYSTROPHY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; TIBIALIS ANTERIOR MUSCLE; TREADMILL EXERCISE; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; C57BL MOUSE; DRUG EFFECT; ELECTROPHYSIOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROELECTRODE; MUSCLE CONTRACTION; MUSCLE ISOMETRIC CONTRACTION; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CALCIUM; CREATINE KINASE; ELECTROPHYSIOLOGY; FLUORESCENT DYES; FURA-2; IMMUNOHISTOCHEMISTRY; ISOMETRIC CONTRACTION; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICROELECTRODES; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; PATCH-CLAMP TECHNIQUES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PHYSICAL CONDITIONING, ANIMAL; REACTIVE OXYGEN SPECIES;

EID: 66149144404     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.90985.2008     Document Type: Article

References (49)

1. Alderton JM, Steinhardt RA. How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc Med 10: 268-272, 2000.
2. Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F, Mantegazza R, Confalonieri P. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 175: 77-86, 2006. (Pubitemid 44235767)
3. Aricha R, Feferman T, Souroujon MC, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 20: 374-376, 2006. (Pubitemid 46671176)
4. Arthur PG, Grounds MD, Shavlakadze T. Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions. Curr Opin Clin Nutr Metab Care 11: 408-416, 2008.
5. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 29: e806, 2007.
6. Bani C, Lagrota-Candido J, Pinheiro DF, Leite PE, Salimena MC, Henriques-Pons A, Quirico-Santos T. Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 37: 583-592, 2008.
7. Basset O, Boittin FX, Cognard C, Constantin B, Ruegg UT. BCL-2 overexpression prevents calcium overload and subsequent apoptosis in dystrophic myotubes. Biochem J 395: 267-276, 2006.
8. Bloom TJ. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can J Physiol Pharmacol 80: 1132-1135, 2002.
9. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 147, Suppl 1: S252-S257, 2006.
10. Burdi R, Didonna MP, Pignol B, Nico B, Mangieri D, Rolland JF, Camerino C, Zallone A, Ferro P, Andreetta F, Confalonieri P, De Luca A. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscul Disord 16: 237-248, 2006.
11. Capkovic KL, Stevenson S, Johnson MC, Thelen JJ, Cornelison DD. Neural cell adhesion molecule (NCAM) marks adult myogenic cells committed to differentiation. Exp Cell Res 314: 1553-1565, 2008.
12. Call JA, Voelker KA, Wolff AV, McMillan RP, Evans NP, Hulver MW, Talmadge RJ, Grange RW. Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract. J Appl Physiol 105: 923-932, 2008.
13. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 433: 317-322, 2005.
14. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65: 826-834, 2005. (Pubitemid 41362124)
15. Combaret L, Ralliere C, Taillandier D, Tanaka K, Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol Biol Rep 26: 95-101, 1999. (Pubitemid 29223258)
16. Danjo W, Fujimura N, Ujike Y. Effect of pentoxifylline on diaphragmatic contractility in septic rats. Acta Med Okayama 62: 101-107, 2008.
17. De Luca A, Nico B, Liantonio A, Didonna MP, Fraysse B, Pierno S, Burdi R, Mangieri D, Rolland JF, Camerino C, Zallone A, Confalonieri P, Andreetta F, Arnoldi E, Courdier-Fruh I, Magyar JP, Frigeri A, Pisoni M, Svelto M, Conte Camerino D. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166: 477-489, 2005. (Pubitemid 40189044)
18. De Luca A, Nico B, Rolland JF, Cozzoli A, Burdi R, Mangieri D, Giannuzzi V, Liantonio A, Cippone V, De Bellis M, Nicchia GP, Camerino GM, Frigeri A, Svelto M, Conte Camerino D. Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 32: 243-253, 2008.
19. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Ruegg UT, Conte Camerino D. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 304: 453-463, 2003. (Pubitemid 36008959)
20. Dorchies OM, Wagner S, Vuadens O, Waldhauser K, Buetler TM, Kucera P, Ruegg UT. Green tea extract and its major polyphenol(-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol 290: C616-C625, 2006.
21. Dudley RW, Danialou G, Govindaraju K, Lands L, Eidelman DE, Petrof BJ. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. Am J Pathol 168: 1276-1287, 2006.
22. Fraysse B, Liantonio A, Cetrone M, Burdi R, Pierno S, Frigeri A, Pisoni M, Camerino C, De Luca A. The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo. Neurobiol Dis 17: 144-154, 2004. (Pubitemid 39345770)
23. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 10: 235-239, 2000. (Pubitemid 30320912)
24. Gosselin LE, Williams JE. Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. Muscle Nerve 33: 820-823, 2006.
25. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31: 1-19, 2008.
26. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18: 676-682, 2004. (Pubitemid 38451789)
27. Hoffman EP, Dressman D. Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends Pharmacol Sci 22: 465-470, 2001. (Pubitemid 32816939)
28. 2+-permeable growth factor-regulated channel. J Cell Biol 161: 957-967, 2003.
29. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci USA 105: 7028-7033, 2008.
30. Kim JS, Diebold BA, Babior BM, Knaus UG, Bokoch GM. Regulation of Nox1 activity via protein kinase A-mediated phosphorylation of NoxA1 and 14-3-3 binding. J Biol Chem 282: 34787-34800, 2007.
31. Kumar A, Boriek AM. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 17: 386-396, 2003. (Pubitemid 36292954)
32. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16: 2702-2713, 2005.
33. Lucas-Heron B, Ollivier B, Schmitt N. Effect of torbafylline on mitochondrial calmitine in mouse skeletal muscle regeneration after injection of a myotoxic drug. J Neurol Sci 118: 97-100, 1993. (Pubitemid 23269974)
34. Lynch GS, Hinkle RT, Faulkner JA. Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. Neuromuscul Disord 11: 192-196, 2001.
35. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 168: 918-926, 2006. (Pubitemid 43327744)
36. Nacci C, Tarquinio M, De Benedictis L, Mauro A, Zigrino A, Carratu MR, Quon MJ, Montagnani M. Endothelial dysfunction in mice with streptozotocin- induced type 1 diabetes is opposed by compensatory overexpression of COX-2 in the vasculature. Endocrinology 150: 849-861, 2009.
37. Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol 172: 233-244, 2006. (Pubitemid 43112970)
38. Rando TA. Oxidative stress and the pathogenesis of muscular dystrophy. Am J Phys Med Rehabil 81: S175-S186, 2002.
39. Roberts P, McGeachie JK. The effects of clenbuterol on satellite cell activation and the regeneration of skeletal muscle: an autoradiographic and morphometric study of whole muscle transplants in mice. J Anat 180: 57-65, 1992.
40. Rolland JF, De Luca A, Burdi R, Andreetta F, Confalonieri P, Conte Camerino D. Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline. Neurobiol Dis 24: 466-474, 2006.
41. Sandri M, Podhorska-Okolow M, Geromel V, Rizzi C, Arslan P, Franceschi C, Carraro U. Exercise induces myonuclear ubiquitination and apoptosis in dystrophin-deficient muscle of mice. J Neuropathol Exp Neurol 56: 45-57, 1997. (Pubitemid 127470326)
42. Schwabe U, Ukena D, Lohse MJ. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 330: 212-221, 1985.
43. Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 11: 2645-2655, 2002.
44. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper [CD4(+)] and cytotoxic [CD8(+)] T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98: 235-243, 2001. (Pubitemid 32150612)
45. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol 158: 1089-1096, 2002.
46. Verde V, Fogliano V, Ritieni A, Maiani G, Morisco F, Caporaso N. Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. Free Radic Res 36: 869-873, 2002.
47. Yablonka-Reuveni Z, Anderson JE. Satellite cells from dystrophic (mdx) mice display accelerated differentiation in primary cultures and in isolated myofibers. Dev Dyn 235: 203-212, 2006. (Pubitemid 46939717)
48. Whitehead NP, Pham C, Gervasio OL, Allen DG. N-acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 586: 2003-2014, 2008.
49. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 33: 657-662, 2006.